Put Options

7 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q1 2024

May 15, 2024

BUY
$56.27 - $73.77 $281,350 - $368,850
5,000 Added 4.77%
109,900 $7.59 Million
Q4 2023

Feb 14, 2024

BUY
$59.06 - $75.72 $1.69 Million - $2.17 Million
28,600 Added 37.48%
104,900 $7.76 Million
Q3 2023

Nov 14, 2023

SELL
$65.94 - $99.04 $1.37 Million - $2.06 Million
-20,800 Reduced 21.42%
76,300 $5.21 Million
Q2 2023

Aug 14, 2023

BUY
$62.68 - $95.05 $908,860 - $1.38 Million
14,500 Added 17.55%
97,100 $9.12 Million
Q1 2023

May 15, 2023

SELL
$47.19 - $70.77 $8.21 Million - $12.3 Million
-173,900 Reduced 67.8%
82,600 $5.6 Million
Q4 2022

Feb 14, 2023

BUY
$30.35 - $53.15 $525,055 - $919,495
17,300 Added 7.23%
256,500 $12.7 Million
Q3 2022

Nov 14, 2022

BUY
$31.97 - $49.37 $885,569 - $1.37 Million
27,700 Added 13.1%
239,200 $7.77 Million

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $7.32B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.